BiotechTube
ImCheck Therapeutics

ImCheck Therapeutics

Marseille, France· Est.
imchecktherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ImCheck Therapeutics is a clinical-stage biotech company developing novel immunotherapies targeting the butyrophilin (BTN) and BTN-like (BTNL) family of immune checkpoints, with a lead program (ICT01) in oncology. Founded in 2015 and based in Marseille, France, the company was recently acquired by Ipsen, a global biopharmaceutical company, in a move that validates its platform and provides significant resources for development. ImCheck's approach aims to activate gamma-delta T cells, a distinct subset of immune cells with potent anti-tumor activity, representing a differentiated strategy in the immuno-oncology landscape.

OncologyInfectious DiseaseAutoimmune Disease

Technology Platform

Platform for developing monoclonal antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of immune checkpoint molecules to modulate gamma-delta T cell function.

Opportunities

The acquisition by Ipsen provides substantial resources and global development expertise to accelerate clinical programs.
The novel mechanism targeting gamma-delta T cells via BTN3A offers a differentiated approach in immuno-oncology with potential in checkpoint-inhibitor non-responders and in difficult-to-treat cancers like AML.

Risk Factors

Clinical development risks remain as ICT01 advances through later-stage trials.
The novel BTN/BTNL target biology is less validated than established checkpoints, posing scientific risk.
Post-acquisition integration into Ipsen's portfolio could lead to strategic shifts or prioritization changes.

Competitive Landscape

The field of gamma-delta T cell engagers is emerging but competitive, with several biotechs exploring antibody or cell-based approaches. ImCheck's specific focus on the BTN3A target provides a distinct mechanism. Its integration into Ipsen now pits it against the clinical and commercial capabilities of larger oncology-focused pharmaceutical companies.

More companies in Immunotherapy / Immuno-Oncology →More companies in France →